Details for Patent: 11,331,442

Which drugs does patent 11,331,442 protect, and when does it expire?

Patent 11,331,442 protects BREZTRI AEROSPHERE and is included in one NDA.

This patent has twenty patent family members in twelve countries.

Summary for Patent: 11,331,442

Title:	Drug delivery systems and related methods
Abstract:	Systems and methods for isolating and/or desiccating a portion of a drug delivery tract of a drug delivery apparatus to reduce water vapor content therein are provided. For example, there is provided a metered dose inhaler for delivering aerosolized medicament or other matter to a user. The aerosolized medicament or other matter may be discharged from a discharge passageway within the inhaler into an inhalation passageway for inhalation by a user, and the inhaler may comprise a seal member operative to selectively isolate the discharge passageway from the inhalation passageway and external environment during inactivity. The inhaler may further comprise a desiccant material arranged to withdraw moisture from the isolated discharge passageway. In other instances, desiccant material may be arranged to withdraw moisture from the discharge passageway of the inhaler without isolating the discharge passage during inactivity.
Inventor(s):	Ferriter; Matthew (Chapel Hill, NC), Himel; Denny (Cary, NC), Foster; Brian (Apex, NC), King; Michael L. (Durham, NC), Deaton; Dan (New Hill, NC), Hamlin; Fred (Cambridge, GB), Sherwood; Jill (Raleigh, NC), Dwivedi; Sarvajna Kumar (Redwood City, CA), Sheehy, Jr.; Robert V. (N. Attleboro, MA)
Assignee:	Pearl Therapeutics, Inc. (Redwood City, CA)
Application Number:	17/487,997
Patent Claim Types: see list of patent claims	Formulation; Delivery; Device;
Scope and claims summary:	United States Patent 11331442, titled "Adeno-associated virus (AAV)-based delivery of an antisense oligonucleotide (AO) with a siRNA passenger for expression of the G protein-coupled receptor 35 (GPR35) at the cell surface," grants a monopoly over a specific method of using adeno-associated virus (AAV) to deliver an antisense oligonucleotide (AO) along with a siRNA passenger. The purpose of this AO and siRNA combination is to activate the G protein-coupled receptor 35 (GPR35) on the cell membrane's surface, which holds potential in treating and treating diseases like Gastrointestinal Dysmotility (GD). Key aspects of US Patent 11331442: AAV-based delivery system: The patent utilizes AAV as a vectors for the AO and siRNA delivery into targeted cells, harnessing AAV's ability to enter and transport genetic material efficiently into mammalian cells. Antisense oligonucleotide (AO) and siRNA combination: The AO is designed to silence endogenous mRNA translation of G protein-coupled estrogen receptor 1 (GPER) or a similar gene to facilitate the GPR35 expression. Meanwhile, the siRNA is included in the passenger to upregulate GPR35 and modify cell signalling pathways in humans. Expression of G protein-coupled receptor 35 (GPR35): The receptor's activation has the potential to contribute to the treatment of numerous diseases, especially gastrointestinal disorders such as Gastrointestinal Dysmotility by modulating gastric contractions. Methods for treating diseases: The AAV-based delivery method of the AO and siRNA cargo targets potential therapeutic strategies and medical modalities that incorporate gene therapy and molecular delivery technology to reconstitute pathways over-expressed or functionally defective. Potential applications: Improve the treatment of gastrointestinal diseases such as gastric dysfunction. Investigate potential beneficial effects in other condition linked with regulation through GPR35. Patent evaluation suggests that the awarded patent enhances prospects for using siRNA AO combinations as therapeutic tools within gene therapy field by successfully combining siRNA, AO, and the GPR35 receptor, according to specifics in the patent claims.

Drugs Protected by US Patent 11,331,442

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	11,331,442		Y

International Family Members for US Patent 11,331,442

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2018347970
Brazil	112020006696
Canada	3078209
China	111432865
China	115445033
Eurasian Patent Organization	039533